EICHORCondition: Head and Neck Squamous Cell Carcinoma · Sponsor: Fulgent Pharma LLC.
The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to characterize the safety and tolerability. Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab in each 28-day cycle.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Highlands Oncology - North Hills | Fayetteville, Arkansas, United States | — |
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles, California, United States | — |
| Moffitt Cancer Center Magnolia Campus | Tampa, Florida, United States | — |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne, Indiana, United States | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas, Texas, United States | — |
| Texas Oncology - Northeast Texas Cancer & Research Institute | Tyler, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06332092